TSN 2898

Drug Profile

TSN 2898

Alternative Names: TSN-2898

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thesan Pharmaceuticals
  • Class Antiacnes; Small molecules
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Acne vulgaris

Most Recent Events

  • 03 May 2017 Thesan Pharmaceuticals withdraws a phase II trial in Acne vulgaris in USA due to unavailability of the drug (NCT02796066)
  • 27 Jun 2016 Clinical trials in Acne vulgaris in USA (Topical) prior to June 2016
  • 26 May 2016 Thesan Pharmaceuticals plans a phase II trial for Acne vulgaris in USA (NCT02796066)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top